Top

Published in:

01-02-2021 | Original Article

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

Authors: Yan Wang, Haiqing Ni, Shuaixiang Zhou, Kaijie He, Yarong Gao, Weiwei Wu, Min Wu, Zhihai Wu, Xuan Qiu, Ying Zhou, Bingliang Chen, Donghui Pan, Chenrong Huang, Mingzhu Li, Yicong Bian, Min Yang, Liyan Miao, Junjian Liu

Published in: Cancer Immunology, Immunotherapy | Issue 2/2021

Abstract

CD47, an immune checkpoint receptor frequently unregulated in various blood and solid tumors, interacts with ligand SIPRα on innate immune cells, and conveys a “do not eat me” signal to inhibit macrophage-mediated tumor phagocytosis. This makes CD47 a valuable target for cancer immunotherapy. However, the therapeutic utility of CD47-SIRPα blockade monoclonal antibodies is largely compromised due to significant red blood cell (RBCs) toxicities and fast target-mediated clearance as a result of extensive expression of CD47 on normal cells. To overcome these limitations and further improve therapeutic efficacy, we designed IBI322, a CD47/PD-L1 bispecific antibody which attenuated CD47 activity in monovalent binding and blocked PD-L1 activity in bivalent binding. IBI322 selectively bound to CD47+PD-L1+ tumor cells, effectively inhibited CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro, but only with minimal impact on CD47 single positive cells such as human RBCs. In addition, as a dual blocker of innate and adaptive immune checkpoints, IBI322 effectively accumulated in PD-L1-positive tumors and demonstrated synergistic activity in inducing complete tumor regression in vivo. Furthermore, IBI322 showed only marginal RBCs depletion and was well tolerated in non-human primates (NHP) after repeated weekly injections, suggesting a sufficient therapeutic window in future clinical development of IBI322 for cancer treatment.

Available only for authorised users

Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11(3):130–135. https://doi.org/10.1016/S0962-8924(00)01906-1CrossRefPubMed

Barclay AN, Berg TKVD (2014) The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 32(1):25–50. https://doi.org/10.1146/annurev-immunol-032713-120142CrossRefPubMed

Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286–299. https://doi.org/10.1016/j.cell.2009.05.045CrossRefPubMedPubMedCentral

Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271–285. https://doi.org/10.1016/j.cell.2009.05.046CrossRefPubMedPubMedCentral

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma. Cell 142(5):699–713. https://doi.org/10.1016/j.cell.2010.07.044CrossRefPubMedPubMedCentral

Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua M-S, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NNH, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci 109(17):6662–6667. https://doi.org/10.1073/pnas.1121623109CrossRefPubMed

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer J-P, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 379(18):1711–1721. https://doi.org/10.1056/NEJMoa1807315CrossRefPubMed

Sallman DA, Donnellan WB, Asch AS, Lee DJ, Malki MA, Marcucci G, Pollyea DA, Kambhampati S, Komrokji RS, Elk JV, Lin M, Agoram B, Chen JY, Volkmer J-P, Takimoto CHM, Chao M, Vyas P (2019) The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: initial phase 1b results. J Clin Oncol 37:7009–7009. https://doi.org/10.1200/JCO.2019.37.15_suppl.7009CrossRef

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O’Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer J-P, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK (2019) First-in-human, first-in-class phase I trial of the anti-cd47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 37(12):946–953. https://doi.org/10.1200/jco.18.02018CrossRefPubMedPubMedCentral

10.

Liu B, Guo H, Xu J, Qin T, Guo Q, Gu N, Zhang D, Qian W, Dai J, Hou S, Wang H, Guo Y (2018) Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. m Abs 10(2):315–324. https://doi.org/10.1080/19420862.2017.1409319CrossRef

11.

Lian S, Xie R, Ye Y, Lu Y, Cheng Y, Xie X, Li S, Jia L (2019) Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Sci Rep 9(1):4532. https://doi.org/10.1038/s41598-019-40241-1CrossRefPubMedPubMedCentral

12.

Liu X, Liu L, Ren Z, Yang K, Xu H, Luan Y, Fu K, Guo J, Peng H, Zhu M, Fu Y-X (2018) Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep 24(8):2101–2111. https://doi.org/10.1016/j.celrep.2018.07.062CrossRefPubMed

13.

Chen L, Han X (2015) Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig 125(9):3384–3391. https://doi.org/10.1172/JCI80011CrossRefPubMed

14.

Sanmamed MF, Chen L (2018) A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175(2):313–326. https://doi.org/10.1016/j.cell.2018.09.035CrossRefPubMedPubMedCentral

15.

Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. https://doi.org/10.1056/NEJMoa1200694CrossRefPubMedPubMedCentral

16.

Wilky BA (2019) Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev 290(1):6–23. https://doi.org/10.1111/imr.12766CrossRefPubMed

17.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690CrossRefPubMedPubMedCentral

18.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167–3175. https://doi.org/10.1200/jco.2009.26.7609CrossRefPubMedPubMedCentral

19.

Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545(7655):495–499. https://doi.org/10.1038/nature22396CrossRefPubMedPubMedCentral

20.

Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16(7):677–681. https://doi.org/10.1038/nbt0798-677CrossRefPubMed

21.

Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, Ni H, Chen B, Xiong Y, Liu Y, Peng B, Yu D, Jiang H, Liu J (2019) Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. Am Abs 11(8):1443–1451. https://doi.org/10.1080/19420862.2019.1654303CrossRef

22.

England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W (2017) Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab. J Nucl Med 58(1):162–168. https://doi.org/10.2967/jnumed.116.177857CrossRefPubMedPubMedCentral

23.

Tavare R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, Witte ON, Ribas A, Wu AM (2016) An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res 76(1):73–82. https://doi.org/10.1158/0008-5472.CAN-15-1707CrossRefPubMed

24.

Chao MP, Majeti R, Weissman IL (2012) Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 12(1):58–67. https://doi.org/10.1038/nrc3171CrossRef

25.

Wu L, Yu G-T, Deng W-W, Mao L, Yang L-L, Ma S-R, Bu L-L, Kulkarni AB, Zhang W-F, Zhang L, Sun Z-J (2018) Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma. OncoImmunology 7(4):e1397248. https://doi.org/10.1080/2162402X.2017.1397248CrossRefPubMedPubMedCentral

26.

Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R (2015) Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE 10(9):e0137345. https://doi.org/10.1371/journal.pone.0137345CrossRefPubMedPubMedCentral

27.

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352(6282):227–231. https://doi.org/10.1126/science.aac9935CrossRefPubMedPubMedCentral

Title: Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Authors: Yan Wang
Haiqing Ni
Shuaixiang Zhou
Kaijie He
Yarong Gao
Weiwei Wu
Min Wu
Zhihai Wu
Xuan Qiu
Ying Zhou
Bingliang Chen
Donghui Pan
Chenrong Huang
Mingzhu Li
Yicong Bian
Min Yang
Liyan Miao
Junjian Liu
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 2/2021
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02679-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis

Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy

Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection

Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors

Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer

The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer